Alright, let's imagine you're playing a game where you try to guess if a balloon will pop or not.

1. **Gilead Sciences** is like the person who brings out the balloons.
2. **$111.18** means that right now, some people think it might be fun to play this game with Gilead's balloons. Their guess is that they won't pop (which in grown-up language means the company is doing well).
3. **1.12%** shows how much more or less people are willing to pay for their guess today compared to yesterday.
4. **Overview** is like a quick look at what's happening with Gilead, what other players think, and if there are any surprises coming up soon (like if they're going to announce something big).
5. **Market News and Data** is just a fancy way of saying "updates on this game."
6. **Benzinga** is like the helper who makes sure everyone gets the right updates at the right time, so you can make better guesses.

So, in simple terms, right now people think Gilead's doing good, and they're a little more excited about it than yesterday, but not too much! Read from source...

It seems like you're asking for a summary of "The Storyteller as Critic" by Walter J. Ong's essay, which examines how oral storytellers functioned as critics within their cultures. Here are the key points:

1. **Inconsistencies and Variations**: Ong argues that oral stories often exhibit inconsistencies when retold, not because of carelessness but due to the nature of orality. Storytellers would adjust narratives based on audience reaction, personal interpretation, or cultural context.

2. **Bias and Partiality**: Oral storytelling is deeply rooted in communal life, which means it naturally reflects the values, beliefs, and biases of the community. The storyteller, acting as both artist and critic, shapes stories to reinforce these shared ideals.

3. **Rational Argument and Emotional Behavior**: Ong suggests that oral storytelling emphasizes emotional appeal over logical argumentation. Storytellers use vivid imagery, repetition, and communal participation (like call-and-response) to engage listeners emotionally.

4. **Criticism as Participation**: In oral cultures, the act of telling a story is itself a form of criticism. The storyteller exercises critical judgment in deciding what to tell, how to tell it, and when to end a story based on audience feedback.

5. **Chiéfic Criticism**: Ong introduces the term 'chiecic' (from the Greek 'chiefein', to criticize) to describe this unique form of criticism exercised by oral storytellers. It's a participatory, communal process that involves both the teller and the listeners.

Based on the provided text, here's a sentiment analysis:

- **Positive:** The article mentions that Gilead Sciences Inc is up 1.12% at $111.18.
- **Neutral:** Most of the information presented is factual and does not express strong opinions.

There doesn't seem to be any **bearish, negative**, or **bullish** sentiments explicitly stated in the given text.

**Investment Recommendations for Gilead Sciences (GILD):**

1. **Analyst Ratings:**
- Buy: 12
- Hold: 9
- Sell: 0
(Data as of [Source], subject to change)

2. **Average Price Target:** $137.41 (Range: $115 to $168)
- Current Price: $111.18

3. **Recommendations:**
- *Morgan Stanley:* Overweight
- *UBS:* Buy
- *BMO Capital Markets:* Outperform
- *Wagner Asset Management:* Buy, price target $168

4. **Risks and Considerations:**

a. **Clinical Trial Results:** GILD's pipeline is dependent on successful clinical trial results. Failure in late-stage trials could lead to delayed or discontinued product launches.

b. **Drug Competition:** The company faces strong competition, especially in the HIV and hepatitis C markets. New treatments or improved existing therapies by competitors could impact GILD's market share.

c. **Patent Expirations:** Key drugs like Harvoni and Sovaldi have already lost patent protection, leading to lower sales due to generic competition. Other patents are expected to expire in the coming years.

d. **Regulatory Risks:** Changes in regulatory environments, both domestic and foreign, can impact GILD's ability to market its products and maintain pricing power.

e. **Market Access Challenges:** Navigating healthcare systems and payer dynamics (e.g., Medicare, Medicaid) to secure favorable reimbursement for products is crucial. Any obstacles could hinder sales growth.

5. **Upside Potential:**
- GILD has a strong cash position ($20.7 billion as of Dec 31, 2022), which can be used for strategic investments, acquisitions, or share repurchases.
- The company's portfolio includes several promising drugs and candidates in various stages of development, such as filgotinib (JAK inhibitor) for rheumatoid arthritis and lenacapavir (long-acting HIV therapy).
- GILD's experience and expertise in developing and commercializing innovative therapies may lead to successful new product launches that could drive growth.

**Disclaimer:** This information is for educational purposes only and does not constitute investment advice. Before making any investment decisions, please conduct thorough research or consult with a financial advisor. Past performance is not indicative of future results.